Melfalanhydrochloride Teva (Melphalan Hydrochloride)

Melphalan hydrochloride forms covalent bonds with the N7 position of guanine bases in DNA, creating cross‑links that block DNA replication and transcription. This disruption leads to cell cycle arrest and apoptosis, primarily affecting rapidly dividing cancer cells.

The dose of melphalan is individualized by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient weight or body surface area, renal function and prior treatment history. No fixed dosing can be provided without a medical prescription.

Melphalan is classified as potentially teratogenic and lacks sufficient safety data for use during pregnancy or lactation. It is generally contraindicated in pregnant or breastfeeding individuals, and effective contraception is advised for both men and women of reproductive potential during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to nitrogen‑mustard alkylators but differs in its pharmacokinetic profile and approved indications. Compared with agents like cyclophosphamide, melphalan is often used for high‑dose regimens in multiple myeloma and certain solid tumours, offering distinct efficacy and toxicity patterns.

Melfalanhydrochloride Teva should be stored at controlled room temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and sources of heat to maintain product stability.

Melphalan is administered intravenously by a qualified healthcare professional. The infusion is typically given over a defined period, as directed by the treating physician, and may be part of a single‑dose or multi‑cycle chemotherapy protocol.

Serious risks include severe neutropenia leading to life‑threatening infections, pulmonary toxicity that can impair breathing, secondary malignancies arising years after treatment, and rare but severe allergic reactions. Patients should be monitored closely for signs of infection, respiratory distress and unexpected skin or systemic reactions.

Melphalan is contraindicated in individuals with known hypersensitivity to nitrogen‑mustard compounds, severe renal or hepatic impairment, active uncontrolled infections, and pregnant or breastfeeding patients. It should also be avoided in patients receiving live vaccines or other highly myelosuppressive therapies without careful medical supervision.